Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of the combination of
niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute